Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis

Anti-Cancer Drugs

Volumn 21, Issue 9, 2010, Pages 877-881

  Kanbayashi, Yuko ^a,c   Hosokawa, Toyoshi ^a,b   Okamoto, Kousuke ^c   Konishi, Hideyuki ^b   Otsuji, Eigo ^b   Yoshikawa, Toshikazu ^b   Takagi, Tatsuya ^c,d   Taniwaki, Masafumi ^b  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY   (Japan)

Author keywords

bortezomib; chemotherapy; oxaliplatin; peripheral neuropathy; taxanes; vincristine

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; AMITRIPTYLINE; ASPARAGINASE; BEVACIZUMAB; BORTEZOMIB; CARBAMAZEPINE; CISPLATIN; CLONAZEPAM; CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GABAPENTIN; MERCAPTOPURINE; MEXILETINE; NONSTEROID ANTIINFLAMMATORY AGENT; OTERACIL POTASSIUM; OXALIPLATIN; PACLITAXEL; PREDNISONE; TAXANE DERIVATIVE; TEGAFUR; THALIDOMIDE; TS 1; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; CANCER PATIENT; DISEASE SEVERITY; FEMALE; HUMAN; HYPOPHARYNX CANCER; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSORY NEUROPATHY; STATISTICAL ANALYSIS;

AGED; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; PERIPHERAL NERVOUS SYSTEM DISEASES; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 77956412774     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32833db89d     Document Type: Article

References (25)

1. Kannarkat G, Lasher EE, Schiff D. Neurologic complications of chemotherapy agents. Curr Opin Neurol 2007; 20:719-725.
2. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008; 13:27-46.
3. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 2008; 44:1507-1515.
4. Park SB, Krishnan AV, Lin CS, Goldstein D, Friedlander M, Kiernan MC. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem 2008; 15:3081-3094.
5. Ocean AJ, Vahdat LT. Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer 2004; 12:619-625.
6. Walker M, Ni O. Neuroprotection during chemotherapy: a systematic review. Am J Clin Oncol 2007; 30:82-92.
7. Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 2007; 110:1042-1049.
8. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008; 112:1593-1599.
9. Ravaglia S, Corso A, Piccolo G, Lozza A, Alfonsi E, Mangiacavalli S, et al. Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clin Neurophysiol 2008; 119:2507-2512.
10. Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006; 24:4507-4514.
11. Kanbayashi Y, Okamoto K, Ogaru T, Hosokawa T, Takagi T. Statistical validation of the relationships of cancer pain relief with various factors using ordered logistic regression analysis. Clin J Pain 2009; 25:65-72.
12. Argyriou AA, Koltzenburg M, Polychronopoulos P, Papapetropoulos S, Kalofonos HP. Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol 2008; 66:218-228.
13. Hagiwara H, Sunada Y. Mechanism of taxane neurotoxicity. Breast Cancer 2004; 11:82-85.
14. Makino H. Treatment and care of neurotoxicity from taxane anticancer agents. Breast Cancer 2004;11:100-104.
15. Ma W, Quirion R. Does COX2-dependent PGE2 play a role in neuropathic pain? Neurosci Lett 2008; 437:165-169.
16. Suyama H, Kawamoto M, Gaus S, Yuge O. Effect of etodolac, a COX-2 inhibitor, on neuropathic pain in a rat model. Brain Res 2004; 1010:144-150.
17. Broom DC, Samad TA, Kohno T, Tegeder I, Geisslinger G, Woolf CJ. Cyclooxygenase 2 expression in the spared nerve injury model of neuropathic pain. Neuroscience 2004; 124:891-900.
18. Vo T, Rice AS, Dworkin RH. Non-steroidal anti-inflammatory drugs for neuropathic pain: how do we explain continued widespread use? Pain 2009; 143:169-171.
19. Kellogg AP, Cheng HT, Pop-Busui R. Cyclooxygenase-2 pathway as a potential therapeutic target in diabetic peripheral neuropathy. Curr Drug Targets 2008; 9:68-76.
20. Kellogg AP, Wiggin TD, Larkin DD, Hayes JM, Stevens MJ, Pop-Busui R. Protective effects of cyclooxygenase-2 gene inactivation against peripheral nerve dysfunction and intraepidermal nerve fiber loss in experimental diabetes. Diabetes 2007; 56:2997-3005.
21. Ja afer FM, Hamdan FB, Mohammed FH. Vincristine-induced neuropathy in rat: electrophysiological and histological study. Exp Brain Res 2006; 173:334-345.
22. Verstappen CC, Koeppen S, Heimans JJ, Huijgens PC, Scheulen ME, Strumberg D, et al. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 2005; 64:1076-1077.
23. Weintraub M, Adde MA, Venzon DJ, Shad AT, Horak ID, Neely JE, et al. Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine. J Clin Oncol 1996; 14:935-940.
24. Gatti A, Sabato AF, Occhioni R, Colini Baldeschi G, Reale C. Controlledrelease oxycodone and pregabalin in the treatment of neuropathic pain: results of a multicenter Italian study. Eur Neurol 2009; 61:129-137.
25. Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 2003; 105:71-78.